November 2, 2026 · Phase 2 readout
TLSA Phase 2 readout: a negative outcome, -16.3%
On November 2, 2026, Foralumab Nasal — Tiziana Life Sciences Ltd (Multiple System Atrophy) reached its Phase 2 readout. The result was a negative outcome, and the stock moved -16.3% in the window around the event. It had already run -28.6% in the 30 days into the catalyst — the kind of pre-event run-up that often precedes binary readouts.
The move
$0.80
1d before
$0.67
Event day
$0.69
1d after
$0.69
5d after
Our prediction vs. the result
CatalystAlert called this one up (+2.6% expected); the stock actually moved -16.3%. Model confidence at the time: 40%.
See the full scored track recordPre-catalyst setup
-28.6%
30-day run-up
7542%
30-day volatility
2.3×
volume spike